Arvinas, Inc.
Arvinas, Inc. (ARVN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ARVN · as of Jun 8, 2026
Key Statistics
Explore Arvinas, Inc. Data
arvn stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 26 · Buy rate: 76.9%
The ARVN analyst consensus is Buy, based on ratings from 26 Wall Street analysts over the past 3 months. The average 12-month price target is $14.75, representing +98.79% upside from the current price of $7.42.
Competitors & Peers
arvn competitorsARVN
ATXS
AVBP
DAWN
DNA
ERASStock Performance
Full HistoryAbout Arvinas, Inc.
Arvinas, Inc. a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates in…
what is arvinas, inc. · arvn stock overview · arvinas, inc. company profile · who is arvinas, inc. ceo · arvn NASDAQ · arvinas, inc. headquarters · arvinas, inc. business segments
About Stock Overview & Key Data
Arvinas, Inc. (ARVN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 27, 2018. As of the latest trading session, ARVN stock price is $7.42, with a market capitalization of $478.7M. The stock has returned -5.24% over the past 12 months and -37.44% year-to-date.
According to 26 Wall Street analysts, the consensus rating for Arvinas, Inc. stock is Buy, with an average 12-month price target of $14.75. In fiscal year 2025, Arvinas, Inc. reported revenue of $262.6M and net income of -$80.8M. For detailed data — including Arvinas, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Arvinas, Inc. (ARVN) stock price is $7.42. The stock is traded on NASDAQ under the ticker symbol ARVN. The 52-week range is $6.06 – $14.51.